STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1/Lines 1-2.	Abstract/Paragraph 1.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2-3/Lines 32-59.	Abstract/Paragraph 1-4.
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 3-4/Lines 63-98.	introduction/ Paragraph 5.
Objectives	3	State specific objectives, including any prespecified hypotheses.	Page 4/Lines 99-100	introduction/ Paragraph 5
Methods				
Study design	4	Present key elements of study design early in the paper	Page 4/ Lines 104	Materials and methods/ Paragraph 6-12
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page3-7/ Lines 104-192	Materials and methods/ Paragraph 6-12
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	(a) Page 3,4,6/ Lines 102-115； 157-160	Materials and methods/ Paragraph 6,10
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case.	N/A, this was no matched study.	N/A, no matched study.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5-7/ Lines 138-178.	Materials and methods/ Paragraph 8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.	Pag e3-4/ Lines 65-74	Materials and methods/ Paragraph 6
Bias	9	Describe any efforts to address potential sources of bias	Page 3-4/ Lines 65-74	Materials and methods/ Paragraph 6
Study size	10	Explain how the study size was arrived at	Page 3-4/ Lines 65-74	Materials and methods/ Paragraph 6
Quantitativ e variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A,this was not quantitative analyse study.	N/A,this was not quantitative analyse study.

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	N/A, Due to the small sample size, there is no need for statistical analysis.	N/A, Due to the small sample size, there is no need for statistical analysis.
		(b) Describe any methods used to examine subgroups and interactions	N/A, there was no subgroups in the study.	N/A, there was no subgroups in the study.
		(c) Explain how missing data were addressed	N/A, this is a respective study and no data was missed.	N/A, this is a respective study and no data was missed.
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A, this is a respective study.	N/A, this is a respective study.
		(e) Describe any sensitivity analyses	N/A, Due to the small sample size, there is no need for sensitivity analysis.	N/A, Due to the small sample size, there is no need for sensitivity analysis.
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 7-8/ Lines 181-187	results/ Paragraph 11
		(b) Give reasons for non-participation at each stage	N/A, this is a respective study.	N/A, this is a respective study.
		(c) Consider use of a flow diagram	N/A, a flow diagram have been shown in Figure 1.	N/A, a flow diagram have been shown in Figure 1.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 7-8/ Lines 181-187	results/ Paragraph 11
		(b) Indicate number of participants with missing data for each variable of interest	N/A, this is a respective study.	N/A, this is a respective study.
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N/A, this is a respective study.	N/A, this is a respective study.
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Page 8-9/ Lines 158-187	results/ Paragraph 12-13
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A, this is a respective study.	N/A, this is a respective study.
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A, this is a respective study.	N/A, this is a respective study.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 8-9/ Lines 188-217	results/ Paragraph 12-13
		(b) Report category boundaries when continuous variables were categorized	N/A, there were no continuous variables in	N/A, there were no continuous variables in

			this study.	this study.
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A, this is a respective study.	N/A, this is a respective study.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A, there was no subgroups in the study	N/A, there was no subgroups in the study
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 9/ Lines 226,227; Page 11/ Lines 226-229;	Discussion/ Paragraph 16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 13-14/ Lines 315-316.	Discussion/ Paragraph 21.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 9-14/ Lines 220-325.	Discussion/ Paragraph 16-21.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11/ Lines 256-261.	Discussion/ Paragraph 18..
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 16/ Lines 356-357	Funding/ Paragraph 28.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www. annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/qims-23-1671
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.